Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study.
Massari F, Mollica V, Fiala O, De Giorgi U, Kucharz J, Vitale MG, Molina-Cerrillo J, Facchini G, Seront E, Lenci E, Bourlon MT, Carrozza F, Pichler R, Lolli C, Myint ZW, Kanesvaran R, Torniai M, Rescigno P, Gomez de Liaño A, Zakopoulou R, Buti S, Porta C, Grande E, Santoni M.
Massari F, et al. Among authors: gomez de liano a.
Eur Urol Oncol. 2024 Oct;7(5):1123-1131. doi: 10.1016/j.euo.2024.03.011. Epub 2024 Apr 4.
Eur Urol Oncol. 2024.
PMID: 38575409